Zapnometinib
- Generic Name
- Zapnometinib
- Drug Type
- Small Molecule
- Chemical Formula
- C13H7ClF2INO2
- CAS Number
- 303175-44-2
- Unique Ingredient Identifier
- 4RZD8LK83V
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Atriva Therapeutics GmbH
- Target Recruit Count
- 96
- Registration Number
- NCT05555823
- Locations
- 🇩🇪
Atriva study site, Neu-Ulm, Germany
Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- Atriva Therapeutics GmbH
- Target Recruit Count
- 133
- Registration Number
- NCT04776044
- Locations
- 🇮🇳
Atriva study site 91004, Raipur, India
🇩🇪Atriva study site 49012, Rostock, Germany
🇩🇪Atriva study site 49013, Berlin, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath